Teva gets FDA approval for cancer drug Israel's Teva Pharmaceutical Industries said the U.S. Food and Drug Administration approved an injectable and infusion version of its cancer drug bendamustine.The drug, sold under the brand name Bendeka, is approved for treating cancer patients with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Teva, which has licensed the drug from Eagle Pharmaceuticals Inc, is responsible for all U.S. commercial activities for Bendeka. (Reporting by Shailesh Kuber; Editing by Saumyadeb Chakrabarty)
Supreme Court rejects challenge to Seattle minimum wage law
Bristol-Myers signs deal with U.N. group for generic hepatitis C drug
UPDATE 2-ArcLight, Freepoint to buy Hovensa St. Croix refinery, plan storage hub